Genmab A/S
AXL-SPECIFIC ANTIBODIES FOR CANCER TREATMENT
Last updated:
Abstract:
The disclosure relates to anti-AXL antibodies, immunoconjugates, and compositions for treatment of cancer, which is resistant to or is predicted to be or become resistant to treatment with a programmed cell death-1/programmed cell death-1 ligand (PD-1/PD-L1) inhibitor.
Status:
Application
Type:
Utility
Filling date:
10 Apr 2019
Issue date:
11 Mar 2021